Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.87 USD | -9.46% | -7.42% | +62.15% |
Financials (USD)
Sales 2024 * | 6.75M | Sales 2025 * | 5.09M | Capitalization | 537M |
---|---|---|---|---|---|
Net income 2024 * | -76M | Net income 2025 * | -91M | EV / Sales 2024 * | 67.6 x |
Net cash position 2024 * | 80.09M | Net cash position 2025 * | 114M | EV / Sales 2025 * | 83 x |
P/E ratio 2024 * |
-7.13
x | P/E ratio 2025 * |
-5.98
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.2% |
Latest transcript on Taysha Gene Therapies, Inc.
1 day | -9.46% | ||
1 week | -7.42% | ||
Current month | -9.18% | ||
1 month | +8.71% | ||
3 months | +61.24% | ||
6 months | -5.28% | ||
Current year | +62.15% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Kamran Alam
DFI | Director of Finance/CFO | 46 | 20-07-31 |
President | 58 | 20-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Donenberg
BRD | Director/Board Member | 63 | 20-08-30 |
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Sean Stalfort
BRD | Director/Board Member | 54 | 23-06-20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.87 | -9.46% | 4,211,874 |
24-03-27 | 3.17 | +3.59% | 2,503,124 |
24-03-26 | 3.06 | 0.00% | 2,145,239 |
24-03-25 | 3.06 | -5.85% | 3,243,077 |
24-03-22 | 3.25 | +4.84% | 3,066,651 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.15% | 537M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |